Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.
Summary
This single-center retrospective study assessed the clinical utility of comprehensive genomic profiling (CGP) in 108 patients with advanced or recurrent non-small cell lung cancer (NSCLC) after standard treatments. CGP detected druggable genetic aberrations in 37% of patients, with EGFR mutations being the most common. Resistance mechanisms were identified in nearly half of patients re-biopsied after targeted therapy. Although CGP-guided therapy was recommended for 35.2% of patients, only 16.6% received it, showing a trend towards prolonged overall survival for this subgroup. The study concludes that CGP can identify actionable mutations missed by conventional diagnostics, thus providing additional therapeutic opportunities in NSCLC.
Analysis
This study is of paramount importance for clinical practice in thoracic oncology. It demonstrates that comprehensive genomic profiling (CGP) can uncover actionable mutations and resistance mechanisms not detected by standard diagnostics, even after initial treatment failure. This opens avenues for additional therapeutic options in patients with advanced NSCLC, where choices are often limited. Identifying these alterations could lead to better personalization of treatments, potentially prolonging survival, and highlights the need to integrate CGP more systematically into NSCLC management, especially in cases of progression.